Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vistin Pharma ASALTS:0RAM 73 Operating Cash Flow per Share is kr1.55 as of Mar. 2026. GuruFocus rates LTS:0RAM with a GF Score™ of 73/100 and a GF Value™ of kr25.98 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 763 Drug Manufacturers companies, Vistin Pharma ASA ranks worse than 131061.47% on this metric.
Vistin Pharma ASA's operating cash flow per share for the
three
months ended in Mar. 2026 was kr-0.08.
Vistin Pharma ASA's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2026 was kr1.55.
During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Vistin Pharma ASA was -32.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Vistin Pharma ASA's Operating Cash Flow per Share or its related term are showing as below:
During the past 13 years, Vistin Pharma ASA's highest 3-Year average Operating Cash Flow per Share Growth Rate was 98.90% per year. The lowest was -48.30% per year. And the median was 9.55% per year.
LTS:0RAM's 3-Year OCF Growth Rate is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.1 * Ranked among companies with meaningful 3-Year OCF Growth Rate only.
Vistin Pharma ASA Operating Cash Flow per Share Related Terms
Vistin Pharma ASA Operating Cash Flow per Share Historical Data
* Premium members only.
The historical data trend for Vistin Pharma ASA's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vistin Pharma ASA Operating Cash Flow per Share Chart
LTS:0RAM vs ZTS, UTHR, VTRS: Operating Cash Flow per Share Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vistin Pharma ASA's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vistin Pharma ASA Price-to-Operating-Cash-Flow vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vistin Pharma ASA's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Vistin Pharma ASA's Price-to-Operating-Cash-Flow falls into.
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr1.55
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Operating Cash Flow per Share of kr1.55 mean?
Vistin Pharma ASA (LTS:0RAM) has a Operating Cash Flow per Share of kr1.55 as of Mar. 2026. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Vistin Pharma ASA and its competitors. According to the industry distribution chart, Vistin Pharma ASA ranks #999999 out of 763 companies in the Drug Manufacturers industry.
Is Vistin Pharma ASA's Operating Cash Flow per Share too high?
Vistin Pharma ASA's current Operating Cash Flow per Share is kr1.55. Based on the distribution chart, Vistin Pharma ASA ranks #999999 out of 763 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Vistin Pharma ASA has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vistin Pharma ASA's Operating Cash Flow per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vistin Pharma ASA ranks #999999 out of 763 companies for Operating Cash Flow per Share. This places Vistin Pharma ASA in the lower half of its industry. The industry median Operating Cash Flow per Share is 7.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Cash Flow per Share for a Drug Manufacturers company?
The median Operating Cash Flow per Share among Drug Manufacturers companies is 7.10, based on 763 companies in the industry. Companies in the top quartile (top 25%) have a Operating Cash Flow per Share significantly above this median, while those in the bottom quartile fall well below. However, Operating Cash Flow per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Cash Flow per Share mean?
A high Operating Cash Flow per Share can signal that a stock is expensive relative to its fundamentals. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Vistin Pharma ASA and its competitors. For the Drug Manufacturers industry, the median Operating Cash Flow per Share is 7.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vistin Pharma ASA's current Operating Cash Flow per Share is kr1.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistin Pharma ASA stock overvalued right now?
Based on GuruFocus' analysis, Vistin Pharma ASA (LTS:0RAM) is currently considered Modestly Undervalued. The stock's GF Value™ is kr25.98, compared to a current price of kr20.00 — trading 23% below its estimated fair value. The current Operating Cash Flow per Share is kr1.55. Vistin Pharma ASA's overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Cash Flow per Share calculated?
Operating Cash Flow per Share is calculated from a company's financial statements. For Vistin Pharma ASA (LTS:0RAM), the current Operating Cash Flow per Share is kr1.55 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vistin Pharma ASA (LTS:0RAM) Overvalued in 2026?
Based on GuruFocus' analysis, Vistin Pharma ASA stock appears to be undervalued.
The current stock price of kr20.00 is trading 23% below its estimated GF Value™ of kr25.98.
GuruFocus considers Vistin Pharma ASA to be Modestly Undervalued.
Key valuation signals for LTS:0RAM:
Operating Cash Flow per Share: kr1.55
GF Value™: kr25.98 vs. price of kr20.00 (23% below fair value)
No single metric tells the full story. See the LTS:0RAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vistin Pharma ASA is a pharmaceutical company engaged in the production and supply of active pharmaceutical ingredients (APIs). The company operates in one business segment, Pharmaceuticals, and is a supplier of Metformin, which is used as a standard treatment for Type 2 diabetes. The company generates revenue across multiple geographic regions, including Africa, Europe, Asia, and North and South America.
73GF Score
Get the complete analysis for LTS:0RAM
Operating Cash Flow per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RAM has been successfully added to your 
